TABLE 2.
Prevalence of drug susceptibility to first-line anti-TB agents
| Drug susceptibility | Total (n = 185) | No. (%)a of isolates grouped by history of TB treatment |
|
|---|---|---|---|
| Primary resistance (n = 144)b | Acquired resistance (n = 41)c | ||
| Pansusceptibled | 138 (74.6) | 114 (79.2) | 24 (58.5) |
| Non-MDRe | 28 (15.1) | 22 (15.3) | 6 (14.6) |
| INH | 13 (7.0) | 9 (6.3) | 4 (9.8) |
| SM | 14 (7.6) | 11 (7.6) | 3 (7.3) |
| RIF | 2 (1.1) | 2 (1.4) | 0 (0.0) |
| EMB | 2 (1.1) | 2 (1.4) | 0 (0.0) |
| MDRf | 19 (10.3) | 8 (5.6) | 11 (26.8) |
a
The percentage in parentheses represents the number of isolates divided by the total number of isolates within each group.
b
Primary resistance was defined as the presence of drug susceptibility in isolates from TB patients who had never received any treatment for TB.
c
Acquired resistance was defined as the presence of drug susceptibility in isolates from TB patients who had a history of previous TB treatment.
d
Pansusceptibility was defined as sensitivity of isolates to all antibiotics.
e
Non-MDR TB was defined as resistance of isolates to at least one drug.
f
MDR TB was defined as resistance of isolates to both INH and RIF.